Phase II trial of MesenCure among 30 patients with serious coronavirus cases shows almost all lived and had shorter hospital stays than controls, but expert says more data needed.

Ten years of research, and an 83 percent survival rate, shows that Gleevec, a cancer drug first developed by an Israeli, can fightt chronic myeloid leukemia.